Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma (Q35754532)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 May 2009

Language	Label	Description	Also known as
English	Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma	scientific article published on 12 May 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

chemoradiotherapy

0 references

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

Joachim Yahalom

4

object named as

Joachim Yahalom

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Alison J Moskowitz

1

object named as

Alison J Moskowitz

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Andrew D Zelenetz

8

object named as

Andrew D Zelenetz

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

author name string

Miguel-Angel Perales

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Tarun Kewalramani

3

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Hugo Castro-Malaspina

5

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Zhigang Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Jill Vanak

7

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Craig H Moskowitz

9

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

language of work or name

0 references

publication date

12 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

146

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

158-163

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278667

2 October 2017

Allogeneic transplantation in lymphoma: current status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278667

2 October 2017

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278667

2 October 2017

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278667

2 October 2017

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278667

2 October 2017

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278667

2 October 2017

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278667

25 September 2018

Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278667

25 September 2018

Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19438504

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19438504

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/19438504

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver

1 reference

https://pubmed.ncbi.nlm.nih.gov/19438504

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19438504

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19438504

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19438504

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2141.2009.07727.X

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35754532&oldid=1721044168"